LT4846B - Junginiai prieš pikornavirusą, jų gavimas ir panaudojimas - Google Patents

Junginiai prieš pikornavirusą, jų gavimas ir panaudojimas Download PDF

Info

Publication number
LT4846B
LT4846B LT2000109A LT2000109A LT4846B LT 4846 B LT4846 B LT 4846B LT 2000109 A LT2000109 A LT 2000109A LT 2000109 A LT2000109 A LT 2000109A LT 4846 B LT4846 B LT 4846B
Authority
LT
Lithuania
Prior art keywords
compound
acceptable salt
prodrug
pharmaceutically acceptable
active metabolite
Prior art date
Application number
LT2000109A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2000109A (en
Inventor
Peter Scott Dragovich
Joseph Timothy Marakovits
Thomas Jay Prins
Jayashree Girish Tikhe
Stephen Evan Webber
Ru Zhou
Theodore O. Johnson
Original Assignee
Agouron Pharmaceuticals,Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals,Inc. filed Critical Agouron Pharmaceuticals,Inc.
Publication of LT2000109A publication Critical patent/LT2000109A/xx
Publication of LT4846B publication Critical patent/LT4846B/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
LT2000109A 1998-04-30 1999-01-05 Junginiai prieš pikornavirusą, jų gavimas ir panaudojimas LT4846B (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8382898P 1998-04-30 1998-04-30
US9835898P 1998-08-28 1998-08-28
PCT/US1999/000260 WO1999057135A1 (en) 1998-04-30 1999-01-05 Antipicornaviral compounds, their preparation and use

Publications (2)

Publication Number Publication Date
LT2000109A LT2000109A (en) 2001-05-25
LT4846B true LT4846B (lt) 2001-10-25

Family

ID=26769788

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2000109A LT4846B (lt) 1998-04-30 1999-01-05 Junginiai prieš pikornavirusą, jų gavimas ir panaudojimas

Country Status (34)

Country Link
US (3) US6531452B1 (pt)
EP (1) EP1073672B1 (pt)
JP (1) JP2003526600A (pt)
KR (1) KR20010043004A (pt)
CN (1) CN1198838C (pt)
AP (1) AP2000001934A0 (pt)
AT (2) ATE248186T1 (pt)
AU (1) AU768539B2 (pt)
BG (1) BG104899A (pt)
BR (1) BR9910573A (pt)
CA (1) CA2326763A1 (pt)
DE (2) DE69910762T2 (pt)
DK (1) DK1073672T3 (pt)
EA (1) EA003856B1 (pt)
EE (1) EE200000621A (pt)
ES (1) ES2205760T3 (pt)
GE (1) GEP20022824B (pt)
HK (1) HK1034722A1 (pt)
HR (1) HRP20000623A2 (pt)
HU (1) HUP0400624A2 (pt)
IL (1) IL138609A0 (pt)
IS (1) IS5633A (pt)
LT (1) LT4846B (pt)
LV (1) LV12666B (pt)
NO (1) NO20005411D0 (pt)
NZ (1) NZ507633A (pt)
OA (1) OA11503A (pt)
PL (1) PL351250A1 (pt)
PT (1) PT1073672E (pt)
SI (1) SI20428A (pt)
SK (1) SK284714B6 (pt)
TR (1) TR200003159T2 (pt)
WO (1) WO1999057135A1 (pt)
YU (1) YU66000A (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9910573A (pt) 1998-04-30 2001-01-16 Agouron Pharma Compostos antipicornavirais, preparação e uso dos mesmos
US6355807B1 (en) 1999-08-24 2002-03-12 Agouron Pharmaceuticals, Inc. Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates
PE20010517A1 (es) * 1999-08-24 2001-05-16 Agouron Pharma Las rutas sinteticas eficientes para la preparacion de los inhibidores de la proteasa del rinovirus y los intermedios claves
US6774243B2 (en) 1999-08-24 2004-08-10 Agouron Pharmaceuticals, Inc. Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates
PE20020157A1 (es) * 1999-12-03 2002-02-22 Agouron Pharma Compuestos derivados de piridona como inhibidores de proteasas de picornaviral 3c, composiciones, sus usos farmaceuticos y materiales para su sintesis
PA8515201A1 (es) 2000-04-14 2002-10-24 Agouron Pharma Compuestos y composiciones antipicornavirales; sus usos farmaceuticos y los materiales para su sintesis
NZ523134A (en) * 2000-06-14 2004-08-27 Agouron Pharma Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
WO2004093860A1 (en) * 2003-04-21 2004-11-04 Pfizer Inc. Inhibitors of sars related coronavirus proteinase
US20040235952A1 (en) * 2003-05-05 2004-11-25 Agouron Pharmaceuticals, Inc. Inhibitors of severe acute respiratory syndrome (SARS) 3C-like proteinase
CN1922137A (zh) * 2003-12-31 2007-02-28 太景生物科技股份有限公司 蛋白酶抑制剂
US7462594B2 (en) 2003-12-31 2008-12-09 Taigen Biotechnology Co., Ltd. Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases
CN100363346C (zh) * 2004-10-22 2008-01-23 清华大学 冠状病毒主蛋白酶的小分子抑制剂、制备方法及其应用
US7893657B2 (en) * 2006-12-19 2011-02-22 Anand Kumar Chavakula Multi-power charger and battery backup system
KR100891699B1 (ko) 2007-04-10 2009-04-03 광주과학기술원 7-아미노-4-((s)-3-(4-플루오로페닐)-2-((r)-3-메틸-2-(5-메틸이소옥사졸-3-카복사미도)부탄아미도)프로판아미도)-7-옥소-2-헵테노에이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 및 치료용 약학적 조성물
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
CA2724785C (en) 2008-05-21 2018-08-07 New World Laboratories Inc. Selective caspase inhibitors and uses thereof
WO2010133000A1 (en) 2009-05-21 2010-11-25 New World Laboratories Inc. Selective caspase inhibitors and uses thereof
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
WO2012140500A1 (en) * 2011-04-15 2012-10-18 New World Laboratories, Inc. Selective cysteine protease inhibitors and uses thereof
CN102838523A (zh) * 2011-06-23 2012-12-26 南开大学 抗肠病毒71(ev71)戊内酰胺类化合物及其制备方法和用途
CN103145608B (zh) * 2011-12-07 2015-09-02 南开大学 抗肠病毒71(ev71)己内酰胺类化合物及其制备方法和用途
RU2518314C2 (ru) * 2012-08-30 2014-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способ и средство активации irf-3 для лечения и профилактики заболеваний, вызываемых (+) phk-содержащими вирусами
CN110105348A (zh) * 2019-03-08 2019-08-09 南开大学 新型迈克尔受体类肠病毒71型抑制剂的制备及用途
MX2021014742A (es) 2019-06-05 2022-02-11 Univ Emory Peptidomimeticos para el tratamiento de infecciones por coronavirus y picornavirus.
WO2021176369A1 (en) 2020-03-06 2021-09-10 Pfizer Inc. Methods of inhibiting sars-cov-2 replication and treating coronavirus disease 2019
CN116648240A (zh) * 2021-01-22 2023-08-25 中国人民解放军军事科学院军事医学研究院 一种环肽类病毒蛋白酶抑制剂,其制备方法,及其在抗病毒药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856530A (en) 1996-05-14 1999-01-05 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
US5962487A (en) 1997-12-16 1999-10-05 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
US6020371A (en) 1997-03-28 2000-02-01 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds compositions containing them and methods for their use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652676A (en) 1985-05-06 1987-03-24 General Foods Corporation L-aminodicarboxylic acid alkenes
AU2251892A (en) 1991-06-14 1993-01-12 Chiron Corporation Inhibitors of picornavirus proteases
US5374623A (en) 1992-08-20 1994-12-20 Prototek, Inc. Cysteine protease inhibitors effective for in vivo use
US5514778A (en) 1993-07-01 1996-05-07 Eli Lilly And Company Anti-picornaviral agents
US5486623A (en) 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
IL112759A0 (en) 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
IT1269511B (it) 1994-05-17 1997-04-01 Univ Degli Studi Milano Derivati di acidi ammino-solfonici , loro impiego nella sintesi di pseudopeptidi e procedimento per la loro preparazione
US5498616A (en) 1994-11-04 1996-03-12 Cephalon, Inc. Cysteine protease and serine protease inhibitors
IT1281031B1 (it) 1995-11-17 1998-02-11 Carlo Chiaves Struttura prefabbricata per la realizzazione di opere costruite a cielo aperto, particolarmente per cavalcavia autostradali,
IL120310A (en) 1996-03-01 2002-02-10 Akzo Nobel Nv Serine protease inhibitors and pharmaceuticals containing them
CA2254343A1 (en) * 1996-05-14 1997-11-20 Agouron Pharmaceuticals, Inc. Inhibitors of picornavirus 3c proteases and methods for their use and preparation
WO1997049668A1 (en) 1996-06-13 1997-12-31 Smithkline Beecham Corporation Inhibitiors of cysteine protease
AU736550B2 (en) * 1997-03-28 2001-08-02 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds, compositions containing them, and methods for their use
US6331554B1 (en) 1997-03-28 2001-12-18 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds, compositions containing them, and methods for their use
BR9910573A (pt) 1998-04-30 2001-01-16 Agouron Pharma Compostos antipicornavirais, preparação e uso dos mesmos
US6369226B1 (en) 1999-06-21 2002-04-09 Agouron Pharmaceuticals, Inc. Substituted benzamide inhibitors of rhinovirus 3C protease
MXPA02001179A (es) 1999-08-04 2002-07-30 Agouron Pharma Compuestos y composiciones antipicornavirales, sus usos farmaceuticos y materiales para su sintesis.
PE20010517A1 (es) 1999-08-24 2001-05-16 Agouron Pharma Las rutas sinteticas eficientes para la preparacion de los inhibidores de la proteasa del rinovirus y los intermedios claves
CN1157391C (zh) 1999-08-24 2004-07-14 阿古龙制药有限公司 制备异噁唑甲酰胺及其类似物的方法和中间体
PE20020157A1 (es) 1999-12-03 2002-02-22 Agouron Pharma Compuestos derivados de piridona como inhibidores de proteasas de picornaviral 3c, composiciones, sus usos farmaceuticos y materiales para su sintesis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856530A (en) 1996-05-14 1999-01-05 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
US6020371A (en) 1997-03-28 2000-02-01 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds compositions containing them and methods for their use
US5962487A (en) 1997-12-16 1999-10-05 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GREEN, WUTZ: "Protecting Groups in Chemical Synthesis (2nd ed.)"

Also Published As

Publication number Publication date
IS5633A (is) 2000-09-22
ATE308557T1 (de) 2005-11-15
CN1198838C (zh) 2005-04-27
AP2000001934A0 (en) 2000-12-31
HRP20000623A2 (en) 2001-04-30
US6995142B2 (en) 2006-02-07
AU2028799A (en) 1999-11-23
IL138609A0 (en) 2001-10-31
DE69910762T2 (de) 2004-03-11
SI20428A (sl) 2001-06-30
EA200001133A1 (ru) 2001-08-27
NO20005411L (no) 2000-10-27
LT2000109A (en) 2001-05-25
US20060046966A1 (en) 2006-03-02
DE69928140D1 (de) 2005-12-08
ATE248186T1 (de) 2003-09-15
EA003856B1 (ru) 2003-10-30
US6531452B1 (en) 2003-03-11
CN1311793A (zh) 2001-09-05
NZ507633A (en) 2003-10-31
US20030130204A1 (en) 2003-07-10
PL351250A1 (en) 2003-04-07
TR200003159T2 (tr) 2001-09-21
WO1999057135A1 (en) 1999-11-11
KR20010043004A (ko) 2001-05-25
LV12666B (lv) 2001-11-20
AU768539B2 (en) 2003-12-18
PT1073672E (pt) 2004-01-30
GEP20022824B (en) 2002-10-25
YU66000A (sh) 2003-12-31
HK1034722A1 (en) 2001-11-02
DK1073672T3 (da) 2003-12-08
JP2003526600A (ja) 2003-09-09
LV12666A (en) 2001-05-20
NO20005411D0 (no) 2000-10-27
EP1073672B1 (en) 2003-08-27
EE200000621A (et) 2002-06-17
ES2205760T3 (es) 2004-05-01
OA11503A (en) 2004-05-10
BG104899A (en) 2001-08-31
BR9910573A (pt) 2001-01-16
DE69910762D1 (de) 2003-10-02
SK16042000A3 (sk) 2001-05-10
SK284714B6 (sk) 2005-09-08
HUP0400624A2 (hu) 2004-06-28
EP1073672A1 (en) 2001-02-07
CA2326763A1 (en) 1999-11-11

Similar Documents

Publication Publication Date Title
LT4846B (lt) Junginiai prieš pikornavirusą, jų gavimas ir panaudojimas
AU779321B2 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
US5962487A (en) Antipicornaviral compounds and methods for their use and preparation
AU736550B2 (en) Antipicornaviral compounds, compositions containing them, and methods for their use
US6906198B1 (en) Antipicornaviral compounds, their preparation and use
EP1329457B1 (en) Antipicornaviral compounds, their preparation and use
MXPA00010406A (en) Antipicornaviral compounds, their preparation and use
CZ20003986A3 (cs) Antipicornavirální součeniny a kompozice, jejich farmaceutické použití a materiály pro jejich syntézu
Obrecht et al. Synthesis, Conformational Properties, and Synthetic Applications of Novel Optically Pure α, α‐Disubstituted (R)‐and (S)‐Glycines (‘α‐Chimeras’) Combining Side Chains of Asp, Glu, Leu, Phe, Ser, and Val

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20050105